Exhibit 99.1

 

LOGO

Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results

WATERTOWN, Mass., March 6, 2014 –

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.

“Our first year as a public company has been a productive one for Tetraphase as we advanced our lead antibiotic candidate, eravacycline, into Phase 3 development and confirmed that we will be pursuing two therapeutic indications for regulatory approval,” said Guy Macdonald, Tetraphase President and Chief Executive Officer. “Notably, through our initial public offering and subsequent follow-on offering, we raised approximately $130 million, funding that we believe will support the company through our planned eravacycline regulatory filing in the U.S. by the end of 2015.”

Mr. Macdonald added: “Eravacycline is the only antibiotic candidate being studied in both IV and oral formulations for the treatment of multi-drug resistant Gram-negative infections in late-stage clinical trials. Given the increasingly favorable regulatory and legislative environments, and the growing recognition of the rising unmet medical need in the Gram-negative antibiotic space by the scientific, pharmaceutical, investment and media communities, we believe we are well positioned to achieve our near-term corporate objectives. We look forward to reporting on our continued progress throughout the year.”

Fourth-Quarter and Full-Year 2013 Financial Results

As of December 31, 2013, Tetraphase had cash and cash equivalents of $102.7 million and 25.6 million shares outstanding.

For the fourth quarter of 2013, Tetraphase reported a net loss of $11.3 million, or $0.49 per share, compared to a net loss of $3.1 million, or $9.43 per share, for the same period in 2012. For the full-year 2013, Tetraphase reported a net loss of $29.6 million, or $1.78 per share, compared to a net loss of $15.1 million or $47.54 per share for the full-year 2012.

Revenues for the fourth quarter of 2013 were $1.9 million compared to $3.2 million for the same period in 2012. Revenues for the full-year 2013 were $10.5 million compared to $7.6 million for the full-year 2012. Revenues for each period consisted of contract and grant revenue under three U.S. government awards for the development of Tetraphase compounds as potential countermeasures for the treatment of diseases caused by bacterial biothreat pathogens. These funds are received through subcontracts and a subaward from CUBRC Inc., an independent, not-for-profit research corporation that specializes in U.S. government-based contracts. These U.S. government awards consist of an award from the Biomedical Advanced Research and Development Authority (BARDA) for eravacycline development and two awards from the National Institute of Allergy and Infectious Diseases (NIAID) for the development of the company’s preclinical compound TP-271. The decrease in revenue during the fourth quarter of 2013


The following information was filed by Tetraphase Pharmaceuticals Inc (TTPH) on Thursday, March 6, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Tetraphase Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tetraphase Pharmaceuticals Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account